Teva Pharmaceutical Indus Q1 2024 Adj EPS $0.48 Misses $0.51 Estimate, Sales $3.819B Beat $3.732B Estimate
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Industries reported its Q1 2024 adjusted earnings per share (EPS) of $0.48, missing the estimated $0.51. However, its sales of $3.819 billion exceeded the expected $3.732 billion.
May 08, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Teva Pharmaceutical Industries reported a Q1 2024 adjusted EPS of $0.48, below the $0.51 estimate, but sales exceeded expectations at $3.819 billion.
The miss in EPS could negatively impact investor sentiment, potentially putting downward pressure on TEVA's stock price. However, the beat on sales might offset this negative impact by indicating stronger than expected revenue generation. The mixed results lead to a neutral short-term price direction expectation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100